Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOTS chemotherapy in locally advanced gastric/GEJ adenocarcinoma
NCT04999332Phase 2Recruiting
- Sponsor
- National Cheng Kung University Hospital
- Start
- Dec 2021
- Primary completion
- Dec 2024
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of folinic acid, oxaliplatin, docetaxel and tegafur in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by National Cheng Kung University Hospital. Primary endpoints: Pathological response and Curative resection rate. Started Dec 2021; status: recruiting.
02
Drugs
folinic acidoxaliplatindocetaxeltegafur
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04999332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04999332.